Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where fasc_issn='0923-7534' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 4711 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Austoker, J
      The potential and pitfalls for developing guidelines in oncology

      ANNALS OF ONCOLOGY
    2. Steer, CB; Marx, GM; Harper, PG
      Is there quality in clinical benefit?

      ANNALS OF ONCOLOGY
    3. Piccart, MJ; Lamb, H; Vermorken, JB
      Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

      ANNALS OF ONCOLOGY
    4. Vasey, PA
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of ovarian cancer

      ANNALS OF ONCOLOGY
    5. Jost, L
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    6. Jost, L
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    7. Wolf, J; Jost, L
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease

      ANNALS OF ONCOLOGY
    8. Huddart, RA
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT)

      ANNALS OF ONCOLOGY
    9. Huddart, RA
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of testicular seminoma

      ANNALS OF ONCOLOGY
    10. Greil, R
      ESMO Recommendations for the application of haematopoietic growth factors (hGFs)

      ANNALS OF ONCOLOGY
    11. Vansteenkiste, JF; Vandebroek, JE; Nackaerts, KL; Weynants, P; Valcke, YJ; Verresen, DA; Devogelaere, RC; Marien, SA; Humblet, YP; Dams, NL
      Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine

      ANNALS OF ONCOLOGY
    12. Skarlos, DV; Samantas, E; Briassoulis, E; Panoussaki, E; Pavlidis, N; Kalofonos, HP; Kardamakis, D; Tsiakopoulos, E; Kosmidis, P; Tsavdaridis, D; Tzitzikas, J; Tsekeris, P; Kouvatseas, G; Zamboglou, N; Fountzilas, G
      Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)

      ANNALS OF ONCOLOGY
    13. Soini, Y; Jarvinen, K; Kaarteenaho-Wiik, R; Kinnula, V
      The expression of P-glycoprotein and multidrug resistance proteins 1 and 2(MRP1 and MRP2) in human malignant mesothelioma

      ANNALS OF ONCOLOGY
    14. O'Shaughnessy, JA; Blum, J; Moiseyenko, V; Jones, SE; Miles, D; Bell, D; Rosso, R; Mauriac, L; Osterwalder, B; Burger, HU; Laws, S
      Randomized, open-label, phase II trial of oral capecitabine (Xeloda((R))) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

      ANNALS OF ONCOLOGY
    15. Skovsgaard, T; Davidson, NGP; Piccart, MJ; Richel, DJ; Bonneterre, J; Cirkel, DT; Barton, CM; Knight, S
      A phase II study of oral eniluracil/fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer

      ANNALS OF ONCOLOGY
    16. Laufman, LR; Spiridonidis, CH; Pritchard, J; Roach, R; Zangmeister, J; Larrimer, N; Moore, T; Segal, M; Jones, J; Patel, T; Gutterman, L; Carman, L; Colborn, D; Kuebler, JP
      Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial

      ANNALS OF ONCOLOGY
    17. Zelek, L; Barthier, S; Riofrio, M; Sevin, D; Fizazi, K; Spielmann, M
      Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes

      ANNALS OF ONCOLOGY
    18. Ulrich-Pur, H; Kornek, GV; Fiebiger, W; Gedlicka, C; Raderer, M; Lenauer, A; Depisch, D; Lang, F; Pidlich, J; Scheithauer, W
      Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy

      ANNALS OF ONCOLOGY
    19. Beer, TM; Pierce, WC; Lowe, BA; Henner, WD
      Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

      ANNALS OF ONCOLOGY
    20. Kostler, WJ; Brodowicz, T; Attems, Y; Hejna, M; Tomek, S; Amann, G; Fiebiger, WCC; Wiltschke, C; Krainer, M; Zielinski, CC
      Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial

      ANNALS OF ONCOLOGY
    21. Punt, CJA; Fumoleau, P; van de Walle, B; Faber, MN; Ravic, M; Campone, M
      Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

      ANNALS OF ONCOLOGY
    22. Quaedvlieg, PFHJ; Visser, O; Lamers, CBHW; Janssen-Heijen, MLG; Taal, BG
      Epidemiology and survival in patients with carcinoid disease in the Netherlands - An epidemiological study with 2391 patients

      ANNALS OF ONCOLOGY
    23. Di Paolo, A; Danesi, R; Falcone, A; Cionini, L; Vannozzi, F; Masi, G; Allegrini, G; Mini, E; Bocci, G; Conte, PF; Del Tacca, M
      Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients

      ANNALS OF ONCOLOGY
    24. Rueffer, U; Breuer, K; Josting, A; Lathan, B; Sieber, M; Manzke, O; Grotenhermen, FJ; Tesch, H; Bredenfeld, H; Koch, P; Nisters-Backes, H; Wolf, J; Engert, A; Diehl, V
      Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment

      ANNALS OF ONCOLOGY
    25. Lagrange, JL; Ramaioli, A; Theodore, C; Terrier-Lacombe, MJ; Beckendorf, V; Biron, P; Chevreau, C; Chinet-Charrot, P; Dumont, J; Delobel-Deroide, A; D'Anjou, J; Chassagne, C; Parache, RM; Karsenty, JM; Mercier, J; Droz, JP
      Non-Hodgkin's lymphoma of the testis: A retrospective study of 84 patientstreated in the French anticancer centres

      ANNALS OF ONCOLOGY
    26. Madroszyk, A; Egreteau, J; Martin, L; Queneau, PE; Bosset, JF; Merrouche, Y
      Small-cell carcinoma of the esophagus: Report of three cases and review ofthe literature with emphasis on therapy

      ANNALS OF ONCOLOGY
    27. Edwards, MJJ; Walker, R; Vinnicombe, S; Barlow, C; MacCallum, P; Foran, JM
      Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma

      ANNALS OF ONCOLOGY
    28. Di Costanzo, F; Gasperoni, S; Falcone, A; Dogliotti, L; Frassinetti, L; Bruzzi, P; Rosso, R
      Repetita iuvant - INTACC (Intergruppo Italiano Terapia Adiuvante Carcinomadel Colon)

      ANNALS OF ONCOLOGY
    29. Wils, J
      Repetita iuvant - INTACC (Intergruppo Italiano Terapia Adiuvante Carcinomadel Colon) - Reply

      ANNALS OF ONCOLOGY
    30. Bertolini, F; Mingrone, W; Alietti, A; Ferrucci, PF; Cocorocchio, E; Peccatori, F; Cinieri, S; Mancuso, P; Corsini, C; Burlini, A; Zucca, E; Martinelli, G
      Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001)

      ANNALS OF ONCOLOGY

    31. How long will we be able to afford increasing costs of healthcare? Or are they truly increasing?

      ANNALS OF ONCOLOGY

    32. Generics or original agents? But which originals?

      ANNALS OF ONCOLOGY

    33. The risks of natural remedies

      ANNALS OF ONCOLOGY

    34. The Peto brothers strike again: On smoking and obesity

      ANNALS OF ONCOLOGY

    35. Oxigene needs some oxygen

      ANNALS OF ONCOLOGY

    36. Bones to chew for the stock market?

      ANNALS OF ONCOLOGY

    37. Talis pater, talis filia

      ANNALS OF ONCOLOGY

    38. A historical victory for Europe?

      ANNALS OF ONCOLOGY

    39. Resistance to STI-571

      ANNALS OF ONCOLOGY

    40. Perhaps not everyone knows that ...

      ANNALS OF ONCOLOGY
    41. McVie, JG
      Are European cancer patients getting a fair deal?

      ANNALS OF ONCOLOGY
    42. Stahel, R; Purkalne, G; Herrstedt, J; Jelic, S; Fervers, B; Kloke, O; Mellstedt, H; Pavlidis, N; Jost, L
      ESMO Minimum Clinical Recommendations - the beginning of a process

      ANNALS OF ONCOLOGY
    43. Glimelius, B
      Chemoradiotherapy for rectal cancer - is there an optimal combination?

      ANNALS OF ONCOLOGY
    44. Luporsi-Gely, E; Pestalozzi, B; Jost, L
      ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer

      ANNALS OF ONCOLOGY
    45. Felip, E
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

      ANNALS OF ONCOLOGY
    46. Felip, E
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC)

      ANNALS OF ONCOLOGY
    47. Plate, S
      ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer

      ANNALS OF ONCOLOGY
    48. Plate, S
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer

      ANNALS OF ONCOLOGY
    49. Briasoulis, E; Tolis, C; Pavlidis, N
      ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)

      ANNALS OF ONCOLOGY
    50. Herrstedt, J
      ESMO Recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV)

      ANNALS OF ONCOLOGY
    51. Marti, JL; Bueso, P; Mayordomo, JI; Isla, MD; Saenz, A; Escudero, P; Murillo, L; Filipovich, E; Andres, R; Tres, A
      Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines

      ANNALS OF ONCOLOGY
    52. Gianni, L; Dombernowsky, P; Sledge, G; Martin, M; Amadori, D; Arbuck, SG; Ravdin, P; Brown, M; Messina, M; Tuck, D; Weil, C; Winograd, B
      Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

      ANNALS OF ONCOLOGY
    53. Vaidya, JS; Baum, M; Tobias, JS; D'Souza, DP; Naidu, SV; Morgan, S; Metaxas, M; Harte, KJ; Sliski, AP; Thomson, E
      Targeted intra-operative radiotherapy (Targit): An innovative method of treatment for early breast cancer

      ANNALS OF ONCOLOGY
    54. Di Leo, A; Larsimont, D; Gancberg, D; Jarvinen, T; Beauduin, M; Vindevoghel, A; Michel, J; Focan, C; Ries, F; Gobert, P; Closon-Dejardin, MT; Dolci, S; Rouas, G; Paesmans, M; Lobelle, JP; Isola, J; Piccart, MJ
      HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide

      ANNALS OF ONCOLOGY
    55. Pergolizzi, S; Settineri, N; Santacaterina, A; Spadaro, P; Maisano, R; Caristi, N; Adamo, V; De Renzis, C; Mesiti, M; Cascinu, S
      Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy

      ANNALS OF ONCOLOGY
    56. Venturini, M; Michelotti, A; Papaldo, P; Del Mastro, L; Bergaglio, M; Lionetto, R; Lunardi, G; Sguotti, C; Frevola, L; Donati, S; Rosso, R; Cognetti, F
      Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients

      ANNALS OF ONCOLOGY
    57. Jacobs, HJM; van Dijck, JAAM; de Kleijn, EMHA; Kiemeney, LALM; Verbeek, ALM
      Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: A simulation study

      ANNALS OF ONCOLOGY
    58. du Bois, A; Luck, HJ; Pfisterer, J; Schroeder, W; Blohmer, JU; Kimmig, R; Moebus, V; Quaas, J
      Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group

      ANNALS OF ONCOLOGY
    59. Saijo, Y; Sato, G; Usui, K; Sato, M; Sagawa, M; Kondo, T; Minami, Y; Nukiwa, T
      Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma

      ANNALS OF ONCOLOGY
    60. Merimsky, O; Staroselsky, A; Inbar, M; Schwartz, Y; Wigler, N; Mann, A; Marmor, S; Greif, J
      Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer

      ANNALS OF ONCOLOGY
    61. Yamada, Y; Shirao, K; Ohtsu, A; Boku, N; Hyodo, I; Saitoh, H; Miyata, Y; Taguchi, T
      Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions

      ANNALS OF ONCOLOGY
    62. Ramanathan, RK; Cnaan, A; Hahn, RG; Carbone, PP; Haller, DG
      Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282

      ANNALS OF ONCOLOGY
    63. Ferrari, S; Bertoni, F; Mercuri, M; Picci, P; Giacomini, S; Longhi, A; Bacci, G
      Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute

      ANNALS OF ONCOLOGY
    64. Rick, O; Beyer, J; Schwella, N; Schubart, H; Schleicher, J; Siegert, W
      Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor

      ANNALS OF ONCOLOGY
    65. Casanova, M; Ferrari, A; Gandola, L; Orlandi, E; Spreafico, F; Terenziani, M; Navarria, P; Luksch, R; Massimino, M; Cefalo, G; Lombardi, F; Fossati-Bellani, F
      Undifferentiated nasopharyngeal carcinoma in children and adolescents: Comparison between staging systems

      ANNALS OF ONCOLOGY
    66. Ferrari, A; Bisogno, G; Casanova, M; Meazza, C; Cecchetto, G; Mancini, MA; Zanetti, I; Alaggio, R; Ninfo, V; Carli, M
      Childhood leiomyosarcoma: A report from theSoft Tissue Sarcoma Italian Cooperative Group

      ANNALS OF ONCOLOGY
    67. Kirchner, EM; Ebsen, M; Kirchner, J; Theegarten, D; Voigtmann, R
      Transformation of Hodgkin's disease to high-grade b-cell lymphoma: Remission after rituximab monotherapy

      ANNALS OF ONCOLOGY
    68. Fakih, M; Schiff, D; Erlich, R; Logan, TF
      Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: A series of six cases

      ANNALS OF ONCOLOGY
    69. Gianni, L; Panzini, I; Tassinari, D; Mianulli, AM; Desiderio, F; Ravaioli, A
      Meta-analyses of randomized trials of adjuvant chemotherapy in gastric cancer

      ANNALS OF ONCOLOGY
    70. Floriani, I; Dell'Anna, T; Mari, E; Torri, V
      Doxorubicin-based chemotherapy in the elderly - Response

      ANNALS OF ONCOLOGY
    71. Sulkes, A; Stemmer, SM
      Doxorubicin-based chemotherapy in the elderly

      ANNALS OF ONCOLOGY
    72. Ibrahim, NK
      Doxorubicin-based chemotherapy in the elderly - Response

      ANNALS OF ONCOLOGY

    73. Royalty implicated in a scandal again?

      ANNALS OF ONCOLOGY

    74. New centre in Italy for breast cancer treatment and research

      ANNALS OF ONCOLOGY

    75. Get set, ready, go and walk briskly: Obesity and cancer go together

      ANNALS OF ONCOLOGY

    76. Proteome and Genome: Where is the new (financial) frontier?

      ANNALS OF ONCOLOGY

    77. Phobias

      ANNALS OF ONCOLOGY

    78. Health research

      ANNALS OF ONCOLOGY
    79. Tattersall, MHN
      Chemotherapy in cervical cancer: Is cisplatin alone still the standard of care?

      ANNALS OF ONCOLOGY
    80. Thomas, DA; Kantarjian, HM
      The revitalization of thalidomide

      ANNALS OF ONCOLOGY
    81. Malafosse, R; Penna, C; Cunha, AS; Nordlinger, B
      Surgical management of hepatic metastases from colorectal malignancies

      ANNALS OF ONCOLOGY
    82. Olopade, OI; Pichert, G
      Cancer genetics in oncology practice

      ANNALS OF ONCOLOGY
    83. Campone, M; Fumoleau, P; Delecroix, V; Deporte-Fety, R; Perrocheau, G; Vernillet, L; Borg-Olivier, O; Louboutin, JP; Bissery, MC; Riva, A; Azli, N
      Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer

      ANNALS OF ONCOLOGY
    84. Knowling, M; Browman, G; Siu, L; Khoo, K; Cooke, A; Tannock, I; Klaassen, D; Cripps, C; Goss, G; Matthews, S; Clarke, R; Seymour, L
      A National Cancer Institute of Canada Clinical Trials Group phase II studyof eniluracil (776C85) and oral 5-fluorouracil in patients with advanced squamous cell head and neck cancer

      ANNALS OF ONCOLOGY
    85. Younes, A; Preti, HA; Hagemeister, FB; McLaughlin, P; Romaguera, JE; Rodriguez, MA; Samuels, BI; Palmer, JL; Cabanillas, F
      Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    86. Hussain, SA; Moffitt, DD; Glaholm, JG; Peake, D; Wallace, DMA; James, ND
      A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer

      ANNALS OF ONCOLOGY
    87. Raderer, M; Osterreicher, C; Machold, K; Formanek, M; Fiebiger, W; Penz, M; Dragosics, B; Chott, A
      Impaired response of gastric MALT-lymphoma to Helicobacter pylori eradication in patients with autoimmune disease

      ANNALS OF ONCOLOGY
    88. Waldherr, C; Pless, M; Maecke, HR; Haldemann, A; Mueller-Brand, J
      The clinical value of [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

      ANNALS OF ONCOLOGY
    89. Shannon, C; Crombie, C; Brooks, A; Lau, H; Drummond, M; Gurney, H
      Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features

      ANNALS OF ONCOLOGY
    90. Castagna, L; Benhamou, E; Pedraza, E; Luboinski, M; Forni, M; Brandes, I; Pico, JL; Dietrich, PY
      Prevention of mucositis in bone marrow transplantation: A double blind randomised controlled trial of sucralfate

      ANNALS OF ONCOLOGY
    91. Quoix, E; Breton, JL; Daniel, C; Jacoulet, P; Debieuvre, D; Paillot, N; Kessler, R; Moreau, L; Coetmeur, D; Lemarie, E; Milleron, B
      Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: A phase II study

      ANNALS OF ONCOLOGY
    92. Dazzi, H; Kaufmann, K; Follath, F
      Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia- Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity inpatients treated for acute leukaemia at theUniversity Hospital of Zurich, Switzerland, between 1990 and 1996

      ANNALS OF ONCOLOGY
    93. Vermorken, JB; Zanetta, G; Oliveira, CFD; van der Burg, MEL; Lacave, AJ; Teodorovic, I; Boes, GH; Colombo, N
      Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma ofthe uterine cervix: An EORTC Gynecological Cancer Cooperative Group study

      ANNALS OF ONCOLOGY
    94. Gallus, S; La Vecchia, C; Levi, F; Simonato, L; Maso, LD; Franceschi, S
      Leanness and squamous cell oesophageal cancer

      ANNALS OF ONCOLOGY
    95. Novak, U; Grob, TJ; Baskaynak, G; Peters, UR; Aebi, S; Zwahlen, D; Tschan, MP; Kreuzer, KA; Leibundgut, EO; Cajot, JF; Tobler, A; Fey, MF
      Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia

      ANNALS OF ONCOLOGY
    96. Bertolini, F; Mingrone, W; Alietti, A; Ferrucci, PF; Cocorocchio, E; Peccatori, F; Cineri, S; Mancuso, P; Corsini, C; Burlini, A; Zucca, E; Martinelli, G
      Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

      ANNALS OF ONCOLOGY
    97. Dimopoulos, MA; Zervas, K; Kouvatseas, G; Galani, E; Grigoraki, V; Kiamouris, C; Vervessou, E; Samantas, E; Papadimitriou, C; Economou, O; Gika, D; Panayiotidis, P; Christakis, I; Anagnostopoulos, N
      Thalidomide and dexamethasone combination for refractory multiple myeloma

      ANNALS OF ONCOLOGY
    98. Veronesi, U; Marubini, E; Mariani, L; Galimberti, V; Luini, A; Veronesi, P; Salvadori, B; Zucali, R
      Radiotherapy after breast-conserving surgery in small breast carcinoma: Long-term results of a randomized trial

      ANNALS OF ONCOLOGY
    99. Emile, JF; Azoulay, D; Gornet, JM; Lopes, G; Delvart, V; Samuel, D; Reynes, M; Bismuth, H; Goldwasser, F
      Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses

      ANNALS OF ONCOLOGY
    100. Icli, F; Akbulut, H; Dincol, D; Onur, H; Demirkazik, A; Cam, R; Cay, F; Demirci, S; Uner, A; Erekul, S
      A randomized trial of four cycles of adjuvant AC (adriamycin plus cyclophosphamide) +/- two cycles of EP (etoposide plus cisplatin) in node positive patients with breast cancer

      ANNALS OF ONCOLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 12:58:03